Activation of PPARγ, a key ligand-dependent transcriptional regulator of adipocytes, is a well-known approach for systemically improving insulin sensitivity, whereas activation of PPARα in the liver is efficient to counteract metabolic disorders of this organ and indirectly alleviates a number of other complex disorders including plasma cholesterol levels or insulin resistance [29]. The gene discussed is INS; the disease is metabolic disease.